23 Apr Take Part in a Global Nature Challenge
Nottingham is taking part for the first time in an annual event to document nature and needs your help...
News
21 Apr Nottingham’s XenoGesis wins prestigious Queen’s Award for Enterprise in recognition of export growth
Nottingham-based leading independent DMPK provider, XenoGesis, has been awarded the prestigious Queen’s Award for Enterprise, International Trade, in recognition of its outstanding year-on-year export growth. XenoGesis is one of only three Nottinghamshire-based companies and 12 in the whole of the East Midlands to receive a Queen’s...
20 Apr Footfalls and Heartbeats launch Masks for the Masses
A company based at Nottingham’s BioCity, has launched a ‘masks for the masses’ campaign selling masks for £6 (£5+VAT) each to the public and donating one for every two sold to charity. The masks are not PPE or medical grade, but do offer at the...
20 Apr Excellerate contribute to success of Omass Therapeutics
Excellerate Bioscience is delighted that a close relationship with Omass Therapeutics, built over 18 months, has helped contribute to their success in securing extended series A funding. During this period, Excellerate assembled a dedicated team of expert pharmacologists focussed exclusively on driving forward the Omass...
15 Apr BioAscent proud to support COVID-19 response
BioAscent is privileged to partner with the University of Glasgow, which is set to host a major COVID-19 testing facility to support the UK and Scottish Governments and NHS efforts against the coronavirus. The facility is part of a series of measures to increase testing in...
15 Apr Alantra Pharma Fast 50 Report – BioAscent tops outsourcing category
The full Alantra Pharma Fast 50 report is now available online and features an in-depth profile of BioAscent, which was recognised as the UK’s fastest-growing drug discovery CRO, coming out top of the outsourcing category and third in the overall listing. Alantra’s annual report on the...
15 Apr XenoGesis supports Sitryx in the Discovery and Development of Immunometabolic Medicines
XenoGesis has been working with biopharmaceutical company Sitryx to support the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory disease in the fast-emerging area of immunometabolism. Sitryx turned to XenoGesis for its scientific expertise and influence in solving the complex...
07 Apr BioCity Glasgow based Amphista Therapeutics raises $7.5m Series A round
Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based BioMotiv Glasgow, Scotland, 7 April 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes...
03 Apr How BioCity based Sygnature Discovery is working on discovering drugs to battle coronavirus
One of Nottingham’s most successful bioscience companies is working towards developing a drug to help treat the deadly coronavirus. Sygnature Discovery, which moved into BioCity in Nottingham city centre in 2004, provides drug discovery and pre-clinical services and expertise to clients across the world. The company has more than...
25 Mar Platelet Services Ltd moves to BioCity Nottingham
Platelet Services Ltd, a contract research organisation providing pre-clinical services in platelet testing moved to BioCity Nottingham facilities in March this year. Platelet Services offers standard and customised platelet testing assays to determine the effect of compounds, or other agents, on platelet function. The company can...